Conference Coverage

Febuxostat increases cardiovascular mortality in CARES trial


 

REPORTING FROM ACC 18

– Long-term treatment with febuxostat in gout patients with comorbid cardiovascular disease conferred significantly higher risks of both cardiovascular death and all-cause mortality, compared with allopurinol, in the Food and Drug Administration–mandated postmarketing CARES trial, William B. White, MD, reported at the annual meeting of the American College of Cardiology.

CARES (Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease) was a prospective, double-blind, 320-center North American clinical trial in which 6,190 patients were randomized to febuxostat (Uloric) at 40-80 mg once daily or 200-600 mg of allopurinol once daily. The postmarketing safety study was required by the FDA as a condition of marketing approval for febuxostat in light of preapproval evidence suggestive of a possible increased risk of cardiovascular events, explained Dr. White, professor of medicine and chief of the division of hypertension and clinical pharmacology at the University of Connecticut, Farmington.

Dr. William B. White, professor of medicine and chief of the division of hypertension and clinical pharmacology at the University of Connecticut, Farmington Bruce Jancin/Frontline Medical News

Dr. William B. White

The primary study endpoint was a composite of cardiovascular death, MI, stroke, and unstable angina resulting in urgent revascularization. In a modified intention-to-treat analysis at a median of 32 and maximum of 85 months of follow-up, the rate was 10.8% in the febuxostat group and similar at 10.4% in the allopurinol group. So there was no safety issue there.

Pages

Recommended Reading

ACC Day 3: Finishing strong in Late-Breaking Clinical Trial Sessions
MDedge Cardiology
Revascularization in paraplegics best performed with PCI
MDedge Cardiology
Post-ACS death lowered in ODYSSEY Outcomes
MDedge Cardiology
VEST: Closer tailoring might boost wearable cardioverter defibrillator’s benefit
MDedge Cardiology
ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
MDedge Cardiology
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
MDedge Cardiology
Wearable defibrillator cuts mortality in post-MI patients
MDedge Cardiology
OSA may provide cardioprotection
MDedge Cardiology
VIDEO: Patient vouchers prompt physicians to prescribe top antiplatelet drugs
MDedge Cardiology
Radial access PCI best for acute coronary syndrome patients
MDedge Cardiology